KURA ONCOLOGY, INC. Other Comprehensive Income (Loss), Net of Tax
KURA ONCOLOGY, INC. (KURA) reported Other Comprehensive Income (Loss), Net of Tax of -$833.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$833.00K.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$1.40M, a 768.57% decline year-over-year.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $207.00K, a 86.89% decline year-over-year.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$263.00K, a 174.50% decline year-over-year.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for fiscal 2025 was $260.00K, a 87.22% decline from fiscal 2024.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $2.04M, a 69.90% decline from fiscal 2023.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $6.76M.
- KURA ONCOLOGY, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$6.24M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$833.00K 10-Q · filed 2026-08-12 | -$2.24M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$1.40M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $260.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $207.00K 10-Q · filed 2025-11-04 | -$56.00K derived: sum of 2 quarters · filed 2026-08-12 | $154.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$263.00K 10-Q · filed 2026-08-12 | -$53.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $210.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $2.04M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $1.58M 10-Q · filed 2025-11-04 | $1.93M derived: sum of 2 quarters · filed 2025-11-04 | $2.39M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $353.00K 10-Q · filed 2025-11-04 | $808.00K derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $455.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $6.76M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $1.69M 10-Q · filed 2024-11-07 | $2.36M derived: sum of 2 quarters · filed 2024-11-07 | $4.50M derived: sum of 3 quarters · filed 2024-11-07 | $5.88M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $674.00K 10-Q · filed 2024-11-07 | $2.81M derived: sum of 2 quarters · filed 2024-11-07 | $4.19M derived: sum of 3 quarters · filed 2025-02-28 | $2.59M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.14M 10-Q · filed 2024-11-07 | $3.52M derived: sum of 2 quarters · filed 2025-02-28 | $1.92M derived: sum of 3 quarters · filed 2025-02-28 | $752.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$217.00K derived: sum of 2 quarters · filed 2025-02-28 | -$1.38M derived: sum of 3 quarters · filed 2025-02-28 | -$6.24M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$1.60M 10-Q · filed 2023-11-02 | -$2.77M derived: sum of 2 quarters · filed 2023-11-02 | -$7.63M 10-Q · filed 2022-11-03 | -$9.22M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.17M 10-Q · filed 2023-11-02 | -$6.03M 10-Q · filed 2022-08-03 | -$7.62M derived: sum of 3 quarters · filed 2024-02-27 | -$7.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$4.86M 10-Q · filed 2023-11-02 | -$6.45M derived: sum of 2 quarters · filed 2024-02-27 | -$6.25M derived: sum of 3 quarters · filed 2024-02-27 | -$6.57M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.40M derived: sum of 2 quarters · filed 2024-02-27 | -$1.71M derived: sum of 3 quarters · filed 2024-02-27 | -$1.83M 10-K · filed 2024-02-27 |
| 2021-09-30 | $199.00K 10-Q · filed 2022-11-03 | -$112.00K derived: sum of 2 quarters · filed 2022-11-03 | -$240.00K 10-Q · filed 2022-11-03 | -$418.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$311.00K 10-Q · filed 2022-08-03 | -$439.00K 10-Q · filed 2022-08-03 | -$617.00K derived: sum of 3 quarters · filed 2023-02-23 | -$950.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$128.00K 10-Q · filed 2022-05-04 | -$306.00K derived: sum of 2 quarters · filed 2023-02-23 | -$639.00K derived: sum of 3 quarters · filed 2023-02-23 | -$643.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$511.00K derived: sum of 2 quarters · filed 2023-02-23 | -$515.00K derived: sum of 3 quarters · filed 2023-02-23 | -$285.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | -$333.00K 10-Q · filed 2021-11-04 | -$337.00K derived: sum of 2 quarters · filed 2021-11-04 | -$107.00K 10-Q · filed 2021-11-04 | -$108.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$4.00K 10-Q · filed 2021-08-05 | $226.00K 10-Q · filed 2021-08-05 | $225.00K derived: sum of 3 quarters · filed 2022-02-24 | $396.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $230.00K 10-Q · filed 2021-05-06 | $229.00K derived: sum of 2 quarters · filed 2022-02-24 | $400.00K derived: sum of 3 quarters · filed 2022-02-24 | $543.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $170.00K derived: sum of 2 quarters · filed 2022-02-24 | $313.00K derived: sum of 3 quarters · filed 2022-02-24 | $462.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $171.00K 10-Q · filed 2020-11-05 | $314.00K derived: sum of 2 quarters · filed 2020-11-05 | $463.00K 10-Q · filed 2020-11-05 | $455.00K derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $143.00K 10-Q · filed 2020-08-06 | $292.00K 10-Q · filed 2020-08-06 | $284.00K derived: sum of 3 quarters · filed 2021-02-24 | $254.00K derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $149.00K 10-Q · filed 2020-05-04 | $141.00K derived: sum of 2 quarters · filed 2021-02-24 | $111.00K derived: sum of 3 quarters · filed 2021-02-24 | $86.00K derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$38.00K derived: sum of 2 quarters · filed 2021-02-24 | -$63.00K derived: sum of 3 quarters · filed 2021-02-24 | -$82.00K 10-K · filed 2021-02-24 |
| 2018-09-30 | -$30.00K 10-Q · filed 2019-11-05 | -$55.00K derived: sum of 2 quarters · filed 2019-11-05 | -$74.00K 10-Q · filed 2019-11-05 | -$109.00K derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | -$25.00K 10-Q · filed 2019-08-01 | -$44.00K 10-Q · filed 2019-08-01 | -$79.00K derived: sum of 3 quarters · filed 2020-02-25 | -$71.00K derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | -$19.00K 10-Q · filed 2019-05-07 | -$54.00K derived: sum of 2 quarters · filed 2020-02-25 | -$46.00K derived: sum of 3 quarters · filed 2020-02-25 | -$49.00K derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$27.00K derived: sum of 2 quarters · filed 2020-02-25 | -$30.00K derived: sum of 3 quarters · filed 2020-02-25 | -$31.00K 10-K · filed 2020-02-25 |
| 2017-09-30 | $8.00K 10-Q · filed 2018-11-05 | $5.00K derived: sum of 2 quarters · filed 2018-11-05 | $4.00K 10-Q · filed 2018-11-05 | |
| 2017-06-30 | -$3.00K 10-Q · filed 2018-08-06 | -$4.00K 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | -$1.00K 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |